Ghent to Use Roche's LightCycler in Cancer Studies | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Scientists at Ghent University in Belgium will use Roche's LightCycler 1536 in various cancer research projects, the company said today.

Ghent researchers will use the technology for multi-gene expression signature profiling on cancer research samples and for digital PCR for sensitive detection of mutant cancer cells in a background of normal cells.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.